Actionable Strategies in Community Oncology to Achieve Equity in Triple-Negative Breast Cancer

This Grand Rounds series focuses on educating, informing, and empowering clinicians involved in the care of patients with triple-negative breast cancer (TNBC) to positively impact the racial/ethnic disparities that negatively impact Black women. Our faculty will explore strategies that promote equitable care and outcomes for all patients; evaluate the role of antibody-drug conjugates (ADCs) in TNBC; and discuss the rapidly evolving clinical practice guidelines, safety and efficacy data of novel therapies, and practical ADC management strategies to anticipate and mitigate adverse events.

Join our expert faculty for this 60-minute program that will help you understand the complexity of TNBC and the far-reaching racial disparities intrinsic to the disease.

• Employ strategies to promote equitable care and outcomes for all patients with TNBC
• Evaluate clinical trial data for ADCs as part of the evolving and expanding TNBC treatment calculus, including recent FDA approvals and updated guideline recommendations
• Incorporate evidence-based treatment plans with an emphasis on the placement of novel therapeutics as part of equitable care for patients with TNBC

Supported through an independent educational grant from Gilead Sciences, Inc.

It is the policy of Creative Educational Concepts, LLC, (CEC) to ensure independence, balance, objectivity, and scientific rigor and integrity in all their CME/CE activities. Activity planners, faculty, peer reviewers, and CEC staff must disclose to the participants any relationships with ineligible entities whose products or devices may be mentioned in this CE activity, or with the commercial supporter of this CE activity. An ineligible entity is defined as any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. Financial relationships may include research grants, consultant fees, travel, advisory boards, consultancy, speakers’ bureaus, other benefits, or having a self-managed equity interest in a company.

CEC has evaluated, identified, and mitigated any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

Planner/Faculty:
Sara Tolaney, MD, MPH–reports the following financial relationships:
Consultant to 4D pharma plc; Aadi Biosciences; Arch Therapeutics, Inc.; AstraZeneca; Athenex, Inc.; Bayer; BeyondSpring Inc.; Blueprint Medicines Corporation; Bristol Myers Squibb Company; Certara, Inc.; Chugai Pharma USA, Inc.; CytomX Therapeutics, Inc.; Daiichi Sankyo, Inc.; Eisai Inc.; Eli Lilly and Company; Ellipses Pharma; Genentech, Inc./Roche; Gilead Sciences, Inc.; Infinity Therapeutics; Menarini/Stemline Therapeutics, Inc.; Merck & Co., Inc.; Mersana therapeutics; Myovant Sciences; Novartis Pharmaceuticals Corporation; Odonate Therapeutics, Inc.; OncoSec Medical Inc.; OncXerna Therapeutics, Inc.; Pfizer Inc.; Sanofi; Seattle Genetics; Inc.; Reveal Genomics; Umoja Biopharma; Zentalis Pharmaceuticals; Zetagen; and Zymeworks Inc.
Research Support (paid to institution) from AstraZeneca; Bristol Myers Squibb Company; Cyclacel Pharmaceuticals, Inc.; Eisai Inc.; Exelixis, Inc.; Genentech, Inc./Roche; Gilead Sciences, Inc.; Lilly; Merck & Co., Inc.; NanoString; Nektar; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Sanofi and Seattle Genetics, Inc.

Faculty:
Sonya Reid, MD, MPH—reports the following financial relationships:
Advisory Board—AstraZeneca, Daiichi Sankyo, Novartis;
Consultant—Agendia;
Research Support/funding to her institution—Komen, BCRF.

Disclosures were obtained from the peer reviewer and Creative Educational Concepts staff—no disclosures to report​

Cristina Rivera Carpenter, PhD, MSN, RN-BC (peer reviewer)​
Katherine E. Lee, PharmD, MPH (planning committee) ​
David Modrak, PhD (planning committee) ​
Nichole Lainhart (planning committee) ​
Janelle Lowrey (planning committee) ​
Sandra Caballero, PharmD (planning committee) ​
Susan H. Yarbrough, CHCP (planning committee) ​
Sharon Tordoff (planning committee)

Faculty of this CME/CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices. CEC, the faculty, and any commercial supporter of this activity do not endorse the use of any product outside of the FDA labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use.